glp-1 neurotransmitter Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression | Pharmacological Reports Glucagon-like peptide-1 - Wikipedia

The most frequent gastrointestinal side effects include: Nausea and vomiting : Very common, typically most pronounced during dose escalation Diarrhoea : Common to very common, though usually mild to moderate Constipation : Can occur due to delayed gastric emptying and reduced gut motility Abdominal pain and discomfort : Common Dyspepsia and gastro-oesophageal reflux : May worsen in susceptible individuals Other important adverse effects include: Gallbladder disorders : Cholelithiasis and cholecystitis have been reported, particularly with weight loss Dehydration and acute kidney injury : May occur secondary to severe gastrointestinal symptoms Hypoglycaemia : Risk increases when used with insulin or sulfonylureas, which may require dose adjustment Current limited evidence does not suggest an increased risk of inflammatory bowel disease (IBD) flares with GLP-1 agonists, though more data are needed

Importantly, when GLP-1 medications are added to insulin or sulfonylureas, doses of these medications may need reduction to prevent hypoglycaemia

Glucagon-like peptide-1 (GLP-1) receptors, which the medication activates to reduce hunger and slow stomach emptying, become less stimulated

When we deliver high-dose vitamin C through IV therapy, your blood levels can reach 80 mg/dLsomething that's impossible to achieve by taking pills